Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and High-School Students.

Autor:	Almendares OM; COVID-19 Response Team., Ruffin JD; COVID-19 Response Team., Collingwood AH; Utah Department of Health and Human Services, Salt Lake City, UT., Nolen LD; Utah Department of Health and Human Services, Salt Lake City, UT., Lanier WA; Center for Preparedness and Response, Division of State and Local Readiness, Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia.; Utah Department of Health and Human Services, Salt Lake City, UT.; US Public Health Service, Rockville, Maryland., Dash SR; Utah Department of Health and Human Services, Salt Lake City, UT., Ciesla AA; COVID-19 Response Team., Wiegand R; COVID-19 Response Team., Tate JE; COVID-19 Response Team., Kirking HL; COVID-19 Response Team.
Jazyk:	angličtina
Zdroj:	Pediatrics [Pediatrics] 2023 Dec 01; Vol. 152 (6).
DOI:	10.1542/peds.2023-062422
Abstrakt:	Background and Objectives: Understanding the real-world impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation measures, particularly vaccination, in children and adolescents in congregate settings remains important. We evaluated protection against SARS-CoV-2 infection using school-based testing data. Methods: Using data from Utah middle- and high-school students participating in school-wide antigen testing in January 2022 during omicron (BA.1) variant predominance, log binomial models were fit to estimate the protection of previous SARS-CoV-2 infection and coronavirus disease 2019 vaccination against SARS-CoV-2 infection. Results: Among 17 910 students, median age was 16 years (range: 12-19), 16.7% had documented previous SARS-CoV-2 infection; 55.6% received 2 vaccine doses with 211 median days since the second dose; and 8.6% of students aged 16 to 19 years received 3 vaccine doses with 21 median days since the third dose. Protection from previous infection alone was 35.9% (95% confidence interval [CI]: 12.9%-52.8%) and 23.8% (95% CI: 2.1%-40.7%) for students aged 12 to 15 and 16 to 19 years, respectively. Protection from 2-dose hybrid immunity (previous SARS-CoV-2 infection and vaccination) with <180 days since the second dose was 58.7% (95% CI: 33.2%-74.4%) for students aged 12 to 15 and 54.7% (95% CI: 31.0%-70.3%) for students aged 16 to 19 years. Protection was highest (70.0%, 95% CI: 42.3%-84.5%) among students with 3-dose hybrid immunity, although confidence intervals overlap with 2-dose vaccination. Conclusions: The estimated protection against infection was strongest for those with hybrid immunity from previous infection and recent vaccination with a third dose.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu